EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 109.16

Change

-0.10 (-0.09)%

Market Cap

USD 0.70B

Volume

7.36K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.01 (-0.03%)

USD 446.30B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.01 (+0.06%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.02 (+0.05%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.11 (-0.38%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.06 (+0.22%)

USD 157.79B
JARI:XETRA Amundi Index Solutions - Amund..

+0.03 (+0.07%)

USD 104.21B
8R80:XETRA Amundi Index Solutions - Amund..

+0.32 (+0.22%)

USD 102.09B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.05 (-0.10%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.76 (-0.71%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-6.12 (-1.00%)

USD 80.38B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.89% 40% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.89% 40% F 40% F
Trailing 12 Months  
Capital Gain 0.22% 14% F 23% F
Dividend Return 1.44% 23% F 21% F
Total Return 1.66% 17% F 24% F
Trailing 5 Years  
Capital Gain 19.89% 47% F 52% F
Dividend Return 8.27% 51% F 38% F
Total Return 28.16% 52% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 7.05% 53% F 53% F
Dividend Return 8.05% 56% F 55% F
Total Return 1.00% 70% C- 49% F
Risk Return Profile  
Volatility (Standard Deviation) 8.29% 69% C- 76% C+
Risk Adjusted Return 97.09% 87% B+ 89% A-
Market Capitalization 0.70B 71% C- 63% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike